NCT01744626View on ClinicalTrials.gov

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Leukemia Lymphocytic Chronic B-Cell
Interventions
DRUG

CC-292

Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28

DRUG

Rituximab

Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle

Trial Locations (8)

35805

Clearview Cancer Institute, Huntsville

38120

The West Clinic, Memphis

47905

Horizon Oncology Research, Inc, Lafayette

50924

Universitätsklinik Köln, Cologne

80804

Städt. Klinikum München-Schwabing, Bayern

89070

Universitätsklinik Ulm, Ulm

907080

Universitatsklinikum Wurzburg, Bayern

07601

Hackensack UMC, Hackensack

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT01744626 - Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter